While the personal benefit of optimizing NAT/AT and decreasing the risk of future metastatic disease is implicit for women with early HER2+ BC, our study reflects the potential for a similarly positive cost benefit of such a strategy to a publicly funded health care system. This evidence concerns the gene ERBB2 and metastatic neoplasm.